PharmaRadar360

PharmaRadar360

ImmunologyDrug intelligence

Skyrizi

Risankizumab

IL-23 p19 inhibitor. Developed by AbbVie. Clinical, regulatory, and source evidence are connected below.

Company
AbbVie
Target / MOA
IL-23 路 IL23A
Aliases
Skyrizi 路 ABBV-066
Signals
24
Clinical trials
20
Approvals
2
Evidence sources
24

Latest signals

What changed

The three most recent source-backed changes linked to this drug.

clinical trialClinicalTrials.gov

Study to Assess Change in Disease Activity of Risankizumab Treatment in Japanese Participants With Moderate to Severe Ulcerative Colitis

N/A 路 RECRUITING 路 AbbVie

clinical trialClinicalTrials.gov

A Study to Assess the Concentrations of Risankizumab in the Breast Milk of Adult Lactating Women With Inflammatory Bowel Disease

Phase 4 路 COMPLETED 路 AbbVie

clinical trialClinicalTrials.gov

Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis

Phase 4 路 COMPLETED 路 AbbVie

Clinical trials

Key active studies

A focused view of recently updated studies 路 20 linked records.

N/ARECRUITINGNCT07136116

Study to Assess Change in Disease Activity of Risankizumab Treatment in Japanese Participants With Moderate to Severe Ulcerative Colitis

AbbVie 路 Updated Mar 3, 2026

Phase 4COMPLETEDNCT06346288

A Study to Assess the Concentrations of Risankizumab in the Breast Milk of Adult Lactating Women With Inflammatory Bowel Disease

AbbVie 路 Updated Feb 27, 2026

Phase 4COMPLETEDNCT05969223

Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis

AbbVie 路 Updated Feb 24, 2026

Phase 3RECRUITINGNCT06100744

A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab

AbbVie 路 Updated Feb 18, 2026

N/ARECRUITINGNCT06764693

An Ex-US Study to Assess Treatment Persistence With Risankizumab in Adult Participants With Psoriatic Arthritis

AbbVie 路 Updated Feb 17, 2026

N/ARECRUITINGNCT06764706

Study to Assess Change in Disease Activity of Risankizumab Treatment in Adult Participants With Moderate to Severe Ulcerative Colitis

AbbVie 路 Updated Feb 17, 2026

Related intelligence

Connected drugs

Records connected through the current intelligence graph.

RinvoqUpadacitinib 路 AbbVie 路 Immunology
HumiraAdalimumab 路 AbbVie 路 Immunology
ImbruvicaIbrutinib 路 AbbVie 路 Oncology
StelaraUstekinumab 路 Johnson & Johnson 路 Immunology
DupixentDupilumab 路 Sanofi 路 Immunology
CosentyxSecukinumab 路 Novartis 路 Immunology

Source evidence

Where this profile comes from

Facts link back to original registries, regulators, labels, and publishers. Counts change as source records update.

ClinicalTrials.govofficial 路 Latest Mar 3, 202620FDAofficial 路 Latest Sep 23, 20222
Professional referenceThis profile summarizes linked public evidence. It is not medical, legal, regulatory, or investment advice. Verify decisions against original sources.